Taiwan Ophthalmology Drug Companies and Pipelines
As of October 22, 2026, this table includes ophthalmic drug or exosome programs at 3 Taiwan companies. [1] [2] [3]
The selected APP13007 is launched in the U.S., BRM411 is in an ongoing Taiwan Phase 2b trial, and ExoTear remains preclinical. [1] [2] [3]
| Company | Ticker | Product / pipeline | Indication | Latest verified stage | Stage source and date | Most recent catalyst |
|---|---|---|---|---|---|---|
| Formosa Pharmaceuticals Company source | 6838 | APP13007 | Inflammation and pain following ocular surgery | U.S. approved and launched; approved in Canada | 2026-10-22 Stage source Successfully obtained US FDA approval | — |
| BRIM Biotechnology Company source | 6885 | BRM411 | Glaucoma | Taiwan Phase 2b ongoing | 2026-09-22 Stage source BRM411 | The September 2026 presentation planned Taiwan Phase 2b completion in Q2 2027; completion is not verified. 2026-09-22 Source BRM411 |
| BIONET Therapeutics Company source | 7808 | ExoTear (stem-cell-derived exosomes) | Dry eye disease | Preclinical | 2026-10-22 Stage source ExoTear | — |
Scope and public-document limits
This is a source-verified selection rather than an industry census. Stages retain their individual source dates; undisclosed names, indications and event dates are not filled in.